IXHL
Incannex Healthcare, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$2.76
−2.13%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +45.9%
- EPS
- +35.5%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +3.2%
- EBIT
- +3.2%
- Net income
- +58.8%
- EPS
- +95.9%
- Free cash flow
- -2.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026